The androgen receptor malignancy shift in prostate cancer
ConclusionsReinterpretation of prostate cancer genomic classification systems in light of the AR malignancy shift may improve our ability to predict clinical outcomes and treat patients appropriately. Identifying and targeting the molecular factors that contribute to the AR malignancy shift is not trivial but by doing so, we may be able to develop new strategies for the treatment or prevention of prostate cancer.
Source: The Prostate - Category: Urology & Nephrology Authors: Ben T. Copeland, Sumanta K. Pal, Eric C. Bolton, Jeremy O. Jones Tags: REVIEW ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Epithelial Cancer | Genetics | Prostate Cancer | Urology & Nephrology